Want to see JP:7774 full AI Analyst Report?
Japan Tissue Engineering Co., Ltd. (7774) AI Stock Analysis
Japan Tissue Engineering Co., Ltd.
(TSE/TYO:7774)
The overall score is at the minimum of the range, reflecting severe fundamental and market challenges. The company's persistent losses and cash burn are the most significant risks, undermining an otherwise debt-free balance sheet. This is compounded by strong bearish technical momentum, with the stock price in a clear downtrend below key moving averages. The negative P/E ratio further confirms the lack of earnings power, leaving no positive catalysts to offset the prevailing weaknesses.
Japan Tissue Engineering Co., Ltd. (7774) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 25.54B
- Dividend Yield
- ―
- Average Volume (3M)
- 118.04K
- Price to Earnings (P/E)
- -58.0
- Beta (1Y)
- 1.22
- Revenue Growth
- 3.43%
- EPS Growth
- -53.59%
- Country
- Japan
- Employees
- 200
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Japan Tissue Engineering Co., Ltd. Business Overview & Revenue Model
Company Description
Japan Tissue Engineering Co., Ltd. operates within the regenerative medicine sector in Japan. The company's activities are organized into three core divisions: Regenerative Medicine Product, Regenerative Medicine Outsourcing, and Research and Develop...
How the Company Makes Money
The company primarily makes money by commercializing regenerative medicine products and associated services. Its core revenue stream is product sales to healthcare providers (typically via Japan’s healthcare reimbursement framework) of approved, tiss...
Japan Tissue Engineering Co., Ltd. Financial Statement Overview
Summary
Financial performance is critically weak. The Income Statement (Score 22) shows persistent net losses and declining revenue, while Cash Flow (Score 18) indicates consistent cash burn. The debt-free Balance Sheet (Score 58) provides some stability, but the overall financial health is precarious due to ongoing unprofitability and eroding equity.
Income Statement
22NegativeBalance Sheet
58NeutralCash Flow
18Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.52B | 2.18B | 2.46B | 2.51B | 2.03B | 2.10B |
| Gross Profit | 1.56B | 1.23B | 1.47B | 1.67B | 1.12B | 1.24B |
| EBITDA | -94.39M | -392.06M | -124.74M | 242.31M | -596.67M | -373.21M |
| Net Income | -440.13M | -734.75M | -255.30M | 143.17M | -729.32M | -497.89M |
Balance Sheet | ||||||
| Total Assets | 5.91B | 5.68B | 6.51B | 6.99B | 6.88B | 7.60B |
| Cash, Cash Equivalents and Short-Term Investments | 3.35B | 3.25B | 3.89B | 4.27B | 4.13B | 4.93B |
| Total Debt | 0 | 0 | 0 | 0 | 133.00K | 936.00K |
| Total Liabilities | 766.06M | 592.71M | 687.95M | 908.43M | 946.15M | 931.66M |
| Stockholders Equity | 5.14B | 5.09B | 5.83B | 6.08B | 5.94B | 6.67B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -562.67M | -224.48M | 78.23M | -771.66M | -327.82M |
| Operating Cash Flow | 0 | -488.02M | -148.37M | 274.14M | -622.60M | -225.25M |
| Investing Cash Flow | 0 | 253.03M | -232.53M | -242.23M | 1.12B | -116.48M |
| Financing Cash Flow | 0 | 0 | -3,000 | -134.00K | -803.00K | -823.00K |
Japan Tissue Engineering Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7774, the sentiment is Negative. The current price of 629.00 is below the 20-day moving average (MA) of 769.95, below the 50-day MA of 817.62, and below the 200-day MA of 673.41, indicating a bearish trend. The MACD of -29.29 indicates Positive momentum. The RSI at 29.07 is Positive, neither overbought nor oversold. The STOCH value of 49.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7774.
Japan Tissue Engineering Co., Ltd. Peers Comparison
Overall Rating
JP:459348Neutral
JP:497845Neutral
JP:459243Neutral- JP:777437Underperform
JP:777637Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:4593 | 48Neutral | JPY 37.00B | 55.04 | ― | ― | -47.32% | ― |
| JP:4978 | 45Neutral | JPY 13.03B | -26.58 | ― | ― | -18.71% | -246.54% |
| JP:4592 | 43Neutral | JPY 71.58B | -19.22 | -37.79% | ― | ― | 5.71% |
| JP:7774 | 37Underperform | JPY 25.54B | -58.02 | ― | ― | 3.43% | -53.59% |
| JP:7776 | 37Underperform | JPY 7.43B | -6.49 | ― | ― | -56.16% | 3.12% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:7774 | Japan Tissue Engineering Co., Ltd. | 629.00 | 153.00 | 32.14% | |
| JP:4592 | SanBio Co | 917.00 | -1913.00 | -67.60% | |
| JP:4593 | Healios KK | 273.00 | -221.00 | -44.74% | |
| JP:4978 | ReproCELL Inc. | 122.00 | -51.00 | -29.48% | |
| JP:7776 | CellSeed Inc. | 188.00 | -249.00 | -56.98% |
Japan Tissue Engineering Co., Ltd. Corporate Events
Japan Tissue Engineering Maintains Profitability as JACC Orders Climb Toward Annual Target
Japan Tissue Engineering reported solid sales growth in the first half of fiscal 2026, with net sales rising to ¥1,499 million and profitability maintained despite one-time expenses booked in the second quarter. Operating profit broke even and n...
Japan Tissue Engineering Returns to Profit as Sales Surge and Forecasts Signal Further Recovery
Japan Tissue Engineering Co., Ltd. reported a sharp year-on-year recovery in results for the six months ended September 30, 2026, with net sales rising 50.1% to ¥1,499 million and returning to a small profit of ¥4 million, compared with a &...
Japan Tissue Engineering Revises FY2026 Financial Disclosure, Lifts Product Business Profit Figure
Japan Tissue Engineering Co., Ltd. has issued a correction to its FY2027 Q1 financial results briefing materials originally disclosed on July 30, 2026, and has posted the revised version on its website. The changes clarify that multiple fiscal-year l...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 31, 2026